211 related articles for article (PubMed ID: 37259801)
41. [Barrett's esophagus].
Neuhaus H
Praxis (Bern 1994); 2004 Nov; 93(47):1951-7. PubMed ID: 15656005
[TBL] [Abstract][Full Text] [Related]
42. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.
Bhat S; Coleman HG; Yousef F; Johnston BT; McManus DT; Gavin AT; Murray LJ
J Natl Cancer Inst; 2011 Jul; 103(13):1049-57. PubMed ID: 21680910
[TBL] [Abstract][Full Text] [Related]
43. Management strategies of Barrett's esophagus.
De Palma GD
World J Gastroenterol; 2012 Nov; 18(43):6216-25. PubMed ID: 23180941
[TBL] [Abstract][Full Text] [Related]
44. Malignant Barrett's oesophagus.
Li H
Eur J Cancer Prev; 1993 Jan; 2(1):47-52. PubMed ID: 8428176
[TBL] [Abstract][Full Text] [Related]
45. [New developments for endoscopic management of Barrett's esophagus with high grade dysplasia].
Wang RH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 39(5):534-41. PubMed ID: 20936731
[TBL] [Abstract][Full Text] [Related]
46. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
47. Endoscopic follow-up and management of Barrett's esophagus in relation to its preneoplastic potential.
Navarro-Dourdil M; Charro-Calvillo M; Uribarrena-Amézaga R; Sebastián-Domingo JJ
Hepatogastroenterology; 2014; 61(133):1241-5. PubMed ID: 25436290
[TBL] [Abstract][Full Text] [Related]
48. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
49. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
50. Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.
Hillman LC; Chiragakis L; Clarke AC; Kaushik SP; Kaye GL
J Gastroenterol Hepatol; 2003 May; 18(5):526-33. PubMed ID: 12702044
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
[TBL] [Abstract][Full Text] [Related]
52. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
Rugge M; Zaninotto G; Parente P; Zanatta L; Cavallin F; Germanà B; Macrì E; Galliani E; Iuzzolino P; Ferrara F; Marin R; Nisi E; Iaderosa G; Deboni M; Bellumat A; Valiante F; Florea G; Della Libera D; Benini M; Bortesi L; Meggio A; Zorzi MG; Depretis G; Miori G; Morelli L; Cataudella G; d'Amore ES; Franceschetti I; Bozzola L; Paternello E; Antonini C; Di Mario F; Dal Bò N; Furlanetto A; Norberto L; Polese L; Iommarini S; Farinati F; Battaglia G; Diamantis G; Realdon S; Guido E; Mastropaolo G; Canova D; Guerini A; Franceschi M; Zirillo M
Ann Surg; 2012 Nov; 256(5):788-94; discussion 794-5. PubMed ID: 23095623
[TBL] [Abstract][Full Text] [Related]
53. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
54. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
55. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study.
de Jonge PJ; van Blankenstein M; Looman CW; Casparie MK; Meijer GA; Kuipers EJ
Gut; 2010 Aug; 59(8):1030-6. PubMed ID: 20639249
[TBL] [Abstract][Full Text] [Related]
56. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
57. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
58. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus.
Gupta N; Gaddam S; Wani SB; Bansal A; Rastogi A; Sharma P
Gastrointest Endosc; 2012 Sep; 76(3):531-8. PubMed ID: 22732877
[TBL] [Abstract][Full Text] [Related]
59. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
60. [Surveillance in Barrett's esophagus].
Leblanc S; Pommaret E; Coriat R; Prat F
Presse Med; 2011 May; 40(5):508-15. PubMed ID: 21450439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]